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Abstract 
The number of the people affected by neurodegenerative disorders is growing dramatically 
due to the aging of population. The major neurodegenerative diseases share some 
common pathological features including involvement of mitochondria in the mechanism of 
pathology and misfolding and accumulation of abnormally aggregated proteins. 
Neurotoxicity of aggregated beta-amyloid, tau, alрha-synuclein and huntingtin is linked to 
effects of these proteins on mitochondria. All these misfolded aggregates affect 
mitochondrial energy metabolism by inhibiting diverse mitochondrial complexes and limits 
ATP availability in neurons. Beta-amyloid, tau, alрha-synuclein and huntingtin are shown to 
be involved in increased production of reactive oxygen species which can be generated in 
mitochondria or can target this organelle. Most of these aggregated proteins are able to 
deregulate mitochondrial calcium handling that in combination with oxidative stress lead to 
opening of the mitochondrial permeability transition pore. Despite some of the common 
features, aggregated beta-amyloid, tau, alpha-synuclein and huntingtin have diverse 
targets in mitochondria that can partially explain neurotoxic effect of these proteins in 
different brain regions. 
 
Introduction 
Aging of the population in the majority of countries leads to increase in the number of 
people with age-related disorders, including neurodegenerative diseases. Despite the 
differences in aetiology and different mechanisms of cell loss, most of neurodegenerative 
disorders share some of common features including the involvement of mitochondrial 
dysfunction and oxidative stress in development of pathology and, specific for each 
disease misfolded proteins which aggregates in the brain of patients. Thus, for Alzheimer’s 
disease there are two misfolded proteins – β-amyloid (main component of the senile 
plaques) and tau protein (aggregates of which form an intracellular tangles) (1). It should 
be noted that tau aggregates are not specific for Alzheimer’s only and appeared in the 
number of other neurodegenerative disorders. Tau mutations are shown to be linked to 
familial form of frontotemporal dementia (2, 3). Second most common neurodegenerative 
disorder – Parkinson’s disease is characterised by intracellular occlusions called Lewy 
bodies, which are formed by aggregated α-synuclein (4). One of the main histopathological 
features of Huntington disease is an aggregate of huntingtin protein (5). All these 
aggregates in the brain consist mostly of protein fibrils and for long time are believed to be 
the trigger of cellular pathology and neurodegeneration in these diseases. Only recently a 
number of studies showed that small oligomeric forms of these proteins are more toxic 
than monomeric or fibril forms.  
Mitochondrion is an organelle which is strongly implicated in the mechanisms of 
neurodegeneration. Being the major energy producer in the cell, mitochondria play 
important role in the mechanism of cell death, calcium and redox signalling (6). Ability of 
mitochondria to produce reactive oxygen species (ROS) in the electron transport chain, 
TCA cycle and some other enzymes has a functional implication in cell signalling, however 
overproduction of ROS in mitochondria links this organelle to the age-related pathology 
and neurodegenerative disorders (7, 8). However, some of the mitochondrial enzymes 
could be specifically linked to functions involved in maintenance of neuronal homeostasis. 
Thus, the enzyme monoamine oxidase, which is located on the outer membrane of 
mitochondria, is involved in the homeostasis of neurotransmitters – dopamine, serotonin 
and norepinephrine (9, 10). Neurons are also dependent on mitochondrial function due to 
several reasons: a) Neurons predominantly produce ATP via oxidative phosphorylation in 
the mitochondria, with almost no contribution from glycolysis; b) The brain consumes 10 
times more oxygen and glucose than any other organ or tissue that may results in higher 
probability of ROS production. c) Neurons are long-lived differentiated cells that are 
therefore more dependent on the processes of mitochondrial dynamics and removal of 
unwanted mitochondria (mitophagy) compare to cells from other tissues. d) Neurons are 
excitable cells with high calcium fluxes. Mitochondria play a role of buffering Ca2+ that 
shapes calcium signals and protects cells from calcium excitotoxicity. e) Neuronal 
processes, that is, axons and dendrites, may be very long and therefore depend on 
mitochondrial transport for transfer of energy molecules to different parts of the cell. 
Because of the importance of all mitochondrial functions to neuronal health, it is perhaps 
understandable why neurons are vulnerable to dysfunction in any mitochondrial pathway. 
Mitochondrial pathology has been associated with a wide range of neurodegenerative 
diseases. In primary mitochondrial diseases, that is, diseases caused by mutations in 
mitochondrial DNA or nuclear DNA encoding mitochondrial proteins, it is clear that 
perturbation in mitochondrial function alone is sufficient and necessary to trigger neuronal 
death. It is less clear whether the mitochondrial dysfunction seen in the sporadic late onset 
neurodegenerative diseases is necessary for pathogenesis or a bystander effect of 
disease, which is mostly associated with misfolded aggregates.  
For long time, the role of misfolded proteins in mitochondrial function was disputable due to 
lack of evidence of location of misfolded aggregates in mitochondria. Recent studies 
demonstrated that aggregated peptides could be delivered to mitochondria (11).  
In this review we discuss the different mechanisms by which misfolded proteins affect 
mitochondrial function and ROS production and how mitochondrial dysfunction and protein 
aggregation could be related to progressive neuronal death in different forms of 
neurodegeneration. 
 
Effects of β-Amyloid on mitochondria 
The amyloid precursor protein (APP) is cleaved by β and γ-secretase generating a range 
of -amyloid (A) peptides between 39 and 43 amino acid residues long, where the 
hydrophobic nature of A 1-40 and A 1-42 promotes self-aggregation and neurotoxicity. A 
series of conformational changes of A via dimers, oligomers, protofibrils and fibrils leads 
ultimately to a deposition of amyloid plaques. 
A shown to have a strong effect on mitochondrial enzymes which contains iron-sulphur 
centre – the most of these enzymes are the complexes of electron transport chain (Figure 
1) and TCA cycle - α-ketoglutarate dehydrogenase and aconitase (12-15). In intact cortical 
and hippocampal neurons, A reduce ATP levels through inhibition of the complexes I and 
IV (16) and induces profound mitochondrial depolarisation of two types – slow 
mitochondrial depolarisation and sharp and transient loss of ∆ψm (17, 18). This 
mitochondrial depolarisation was dependent on the βA-induced calcium signal (17, 19) and 
induction of ROS overproduction from NADPH oxidase (20, 21). Deregulation of calcium 
homeostasis has been demonstrated in Alzheimer’s disease (AD), with A causing 
increased cytoplasmic calcium levels and mitochondrial calcium overload, resulting in 
increase in ROS production and opening of the PTP (19, 20). βA is able to induce opening 
of PTP in isolated mitochondria (22, 23) and primary astrocytes (17, 24, 25). Furthermore 
A may directly interact with cyclophilin D (a PTP component) forming a complex in the 
mitochondria that has reduced threshold for opening in the presence of mPTP inducers. 
Prevention of PTP opening by inducing cyclophilin D deficiency (molecular inhibition of 
PTP opening) is also able to improve mitochondrial function and learning/memory in an 
aging AD mouse model (26). 
A reduction in complex IV activity has been demonstrated in mitochondria from the 
hippocampus and platelets of AD patients, as well as in AD animal models and AD cybrid 
cells (27). Aggregation of A leads to oxidative stress, mitochondrial dysfunction and 
energy failure prior to the development of plaque pathology (28). Activation of the DNA 
repairing enzyme PARP in AD due to overproduction of ROS in NADPH oxidase leads to 
consumption of NAD and restriction of substrates (Figure 1) for mitochondrial complex I, 
resulting in collapse in bioenergetics and cell death (29, 30). Provision of mitochondrial 
substrates can prevent amyloid induced cell death (17, 21). A perturbation in mitochondrial 
dynamics has also been described in AD human brain and cell models. Fragmented 
mitochondria are seen in AD hippocampus in association with a downregulation of 
mitochondrial fusion proteins (MFN-1, MFN-2, OPA-1), with an increase in expression of 
the mitochondrial fission protein Fis-1 (31).  
Mitochondria also can regulate aggregation of βA, tau or alpha-synuclein. Inorganic 
polyphosphate plays important signalling role in brain (32, 33) and in mammalian cells 
produced in mitochondria (34). Inorganic polyphosphate accelerates aggregation of βA, 
tau and alpha-synuclein forming non-toxic fibrils playing role cytoprotective modifier (35). 
 
Role of tau in mitochondrial physiology and pathology 
Tau protein (tubulin-associated unit) refers to microtubule-associated proteins. It is a 
soluble, natively unfolded, and phosphorylated protein, ubiquitously expressed in most 
tissues and organs. This protein exists as six alternatively spliced isoforms and is encoded 
by a single gene, mapt, that is located on chromosome 17 in humans (36). Tau is found in 
all cellular and subcellular compartments but is most prominent in the axons of neurons of 
the central nervous system (37, 38). Tau protein plays an important role in neuronal 
physiology, in microtubule assembly and dynamics (39), in promoting axonal out growth 
(40), axonal transport and in signal transduction (41). Physiological and pathological 
activity of tau is dependent on the phosphorylation (tau is phosphoprotein) and alternative 
splicing and on the level of aggregation. The soluble prefibrillar aggregates of tau proteins 
cause the most damage to neurons. In disease, tau dissociates from microtubules and 
forms large, primarily intracellular, β-sheet rich fibrils (42). Tau protein is involved in the 
pathogenesis of many neurodegenerative diseases, specifically in Alzheimer’s disease and 
frontotemporal dementia. Pathologies and dementias of the nervous system are 
associated with tau proteins that have become defective and no longer stabilize 
microtubules properly. The abnormal tau function leads to the deficits in fast axonal 
transport, dystrophic neurites, and abnormal mitochondrial distribution (43-45). This 
abnormal distribution of mitochondria is more likely to be induced by impairment the fission 
and fusion of mitochondria by tau (46). It also have been shown that in human tau 
transgenic mice and flies, F-actin is increased, which disrupts the physical association of 
mitochondria and the fission protein DRP1 (Figure 1), leading to mitochondrial elongation 
(46). The resulting neurotoxicity can be rescued either by reducing mitochondrial fusion, or 
by enhancing fission, or by reversing actin stabilization. The possible effect of tau on 
mitochondrial complex I have been shown triple knockout Alzheimer’s disease mouse 
mitochondria (47). The 10+16 intronic mutation in MAPT gene, encoding tau increase in 
the production of 4R tau isoforms, which are more prone to aggregation. Human iPSC 
derived neurons with this mutation are associated with partially suppressed complex I-
driven respiration that lead to F1Fo-ATPase to be switched in reverse mode. This 
combination increased mitochondrial membrane potential that trigger ROS production in 
electron transport chain which causes oxidative stress and cell death (48). 
 
Role of α-synuclein in mitochondrial physiology and pathology 
α-Synuclein is strongly implicated in pathology of Parkinson’s disease as a main 
component of Lewy body – neuronal aggregated inclusions. Lewy body is one of the major 
pathological hallmarks of this neurodegenerative disorder. One of autosomal-dominant 
familial Parkinson’s disease can be attributed solely to mutations in the SNCA gene (which 
encoded α-synuclein) or by genetic duplication or triplication of the wild-type SCNA locus 
(49). Native monomeric form of α-synuclein is soluble protein which aggregates to form 
insoluble fibrils via a series of conformational changes including most toxic intermediates – 
oligomeric.  
Monomeric α-synuclein plays important physiological roles in synaptic signal transduction 
(50, 51) and as a regulator ATP production (Figure 1). Thus, monomeric α-synuclein binds 
F0-F1-ATPsynthase and increase efficiency of this enzyme to produce ATP (52). 
Monomeric, oligomeric and fibrillary α-synucleins are able to penetrate through plasma and 
intracellular membranes (53, 54). The high degree of curvature of mitochondrial 
membranes and the presence of cardiolipin contribute to the interaction of α-synuclein with 
this organelle. It is known that α-synuclein preferentially binds to negatively charged lipids 
(55-58). Previously, it has been found that α-synuclein specifically binds to mitochondria 
but no other cell organelles (53, 59). 
Parkinson’s disease is linked to mitochondrial abnormalities more than any other 
neurodegenerative disorder. It has been proven by toxins (rotenone and MPTP) and by the 
fact that most of the familial forms of Parkinson’s disease are associated with 
mitochondria. Pathogenesis of Parkinson’s disease is characterized by decreased activity 
of mitochondrial respiratory chain complex I in the nigrostriatal system by 25-30%. 
Importantly, oligomeric α-synuclein is able to inhibit complex I (60, 61) or even damage this 
component of electron transport chain (62). In agreement to this oligomeric α-synuclein 
had no effect on the neurons with complex I mutation (63). In transgenic mice 
overexpressing a wild-type α-synuclein occur not only breach morphology, loss of 
mitochondrial membrane potential (Δψ), and fragmentation of the mitochondria, 
predisposing to neurodegeneration (64-66). 
Mitochondria play important role in maintenance of calcium homeostasis in physiology and 
pathology (67). For monomeric and oligomeric α-synuclein shown ability to stimulate 
calcium signal (Figure 1) by incorporation into plasma membrane and forming a pore (68, 
69). Mitochondrial calcium overload and reactive oxygen species are the major triggers for 
mitochondrial permeability transition pore (mPTP) (70). Although activation of production of 
ROS in mitochondria by α-synuclein is disputable it was shown recently that β-sheet-rich α-
synuclein oligomers, and to a lesser extent α-synuclein fibrils are initiated of increase ROS 
production and lipid peroxidation (71, 72) Ability of oligomeric (but not monomeric) α-
synuclein to induce both calcium rise and ROS production increases the probability of 
mPTP opening. However, using of purified recombinant human α-synuclein on isolated 
mitochondria it has been shown that the addition of oligomeric forms of α-synuclein 
reduced retention time exogenously added Ca2+, promoted of Ca2+ induced swelling and 
mitochondrial depolarization and accelerated secretion of cytochrome C. Inhibition of 
mPTP prevented these oligomer-induced changes of mitochondrial parameters (61).  
In all eukaryotic cells, endoplasmic reticulum (ER) and mitochondria interact closely using 
a specific sub-domains of ER and MITO membrane, forming MAM structures 
(mitochondria-associated membranes, see Figure 1) (73). MAM site of ER has a unique 
lipid composition, enriched of cholesterol and the anionic phospholipids, with the 
characteristics of the lipid raft (74). It has been shown that α-synuclein affects a key MAM 
function - calcium transport between the ER and mitochondria and the wild type α-
synuclein from cell lines and brain tissue of human and mouse is present in MAM 
structures (73, 75). It was found that pathogenic point mutations in human α-synuclein 
result in its reduced association with MAM, coincident with a lower degree of apposition of 
ER with mitochondria, a decrease in MAM function, and an increase in mitochondrial 
fragmentation compared with wild-type (76). 
α-Synuclein can interfere with number of mitochondrial transport proteins including TOM 
machinery and VDAC (57). Thus, it was shown that certain types of post-translationally 
modified α-synuclein binds with high affinity to the receptor TOM20, related to 
mitochondrial protein importing machinery TOM. This binding prevented the interaction of 
TOM20 with its co-receptor, TOM22, and impaired mitochondrial protein import (77). 
 
Huntingtin protein and mitochondria 
Huntington's disease is neurodegenerative disorder caused by mutation of a CAG repeat 
located in exon 1 of Huntingtin gene. Vulnerability and degeneration of striatal neurons are 
the first obvious signs of early-grade Huntington's disease. Importantly, a mutation of 
huntingtin protein (Htt) changes the location of this protein from the nucleus and cytoplasm 
for wild type Htt to mitochondria for mutant Htt (78, 79). For wild type Htt the role in vesicle 
trafficking, secretion pathways and apoptosis was demonstrated (80, 81). 
The Htt function should affect a multitude of signalling pathways that could be confirmed by 
lethality of htt knockout mouse model (82).  
The co-localisation of mutant Htt to the mitochondria leads to inhibition of electron transport 
chain and reduction of energy levels in Huntington's disease which initiates striatal cell 
death (Figure 1). Expression of mutant Htt in mice resulted in a reduced mitochondrial 
membrane potential, suggesting that one or more of the electron transport chain 
complexes are not working correctly. Thus, in mice with mutated Htt activity of the complex 
II and complex IV is reduced and expression of mitochondrial complex II is also 
significantly decreased (83-85). Lower mitochondrial membrane potential in neurons with 
mutated Htt leads to dramatically reduced calcium buffering capacity (86). Lower 
mitochondrial buffering capacity in cells with mutated Htt could be the reason for induction 
of mitochondrial PTP and cell death (87). 
 
Conclusions and future directions 
Despite the difference in toxicity between βA, α-synuclein, tau and Htt and their original 
location (extracellular, intracellular or membranes) all these misfolded proteins and 
peptides have similarities in the mechanisms of neurodegeneration induced by their 
aggregates. One of the most important steps is an induction of oligomerisation of these 
peptides. Considering possible role of monomers (α-synuclein, tau and huntingtin) in cell 
physiology aggregation of these peptides is the initial step in the mechanism of their 
toxicity. Although all these misfolded proteins initiate ROS production and inhibit 
mitochondrial respiration via different mechanisms, it results in induction of cell death 
through opening of mPTP.  
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Figure legend 
Figure 1. Effects of the major misfolded proteins on mitochondria. Beta-amyloid, tau, 
alpha-synuclein and huntingtin protein have a direct effect on mitochondria. Oligomeric 
beta-amyloid, alpha-synuclein and huntingtin protein inhibit complexes of electron transport 
chain, tau play important role in mitochondrial dynamics. Mitochondrial dysfunction induced 
by aggregated proteins lead to neuronal cell death 
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